Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 3/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8614363 | 0.98 | ADRA1A (0.43) | ADRA1AP2RX7CHRNB2CHRNA4PIK3CD | |
| SCHEMBL8616078 | 0.81 | SLC18A3 (0.36) | ADRA1A | |
| SCHEMBL7644557 | 0.81 | DRD2 (0.39) | ADRA1ACHRNB2CHRNA4 | |
| SCHEMBL7681696 | 0.81 | ADRA1A (0.34) | ADRA1ACYP2D6 | |
| SCHEMBL936991 | 0.80 | SLC6A4 (0.40) | CHRNB2CHRNA4 | |
| SCHEMBL7643514 | 0.80 | SLC6A4 (0.40) | P2RX7 | |
| Hydrochloric Acid SCHEMBL2918744 | 0.79 | SLC6A4 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL8611307 | 0.75 | CHRNB2 (0.39) | CHRNB2CHRNA4MEN1RECQLKMT2A | |
| SCHEMBL232190 | 0.74 | — | — | |
| SCHEMBL5827498 | 0.74 | PNMT (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026357-B2 | Diphenylurea compounds | LES LABORATOIRES SERVIER (FR) | 2006-04-11 | — | — | US | disclosed |
| EP-1170288-B9 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | SERVIER LAB (FR) | 2005-01-26 | — | — | EP | disclosed |
| US-20040224993-A1 | Diphenylurea compounds | LAVIELLE GILBERT (FR) | 2004-11-11 | — | — | US | disclosed |
| US-6784183-B2 | ANTISEROTONINE AGENTS | LES LABORATOIRES SERVIER (FR) | 2004-08-31 | — | — | US | disclosed |
| EP-1170288-B1 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | SERVIER LAB (FR) | 2004-08-11 | — | — | EP | disclosed |
| US-20020025965-A1 | Antiserotonine agents | ADIR ET COMPAGNIE (FR) | 2002-02-28 | — | — | US | disclosed |
| EP-1170288-A2 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | LES LABORATOIRES SERVIER (FR) | 2002-01-09 | — | — | EP | disclosed |
| EP-0618906-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | JUVANTIA PHARMA LTD OY (FI) | 1998-04-22 | — | — | EP | disclosed |
| US-5498623-A | MULTISTAGE REACTION FOR HALOGENATION OF COMPOUNDS, NITRATION, REDUCTION AND CONVERSION TO DIAZONIUM SALT THEN HALOGENATION FOR COGNITIVE DISORDERS | ORION-YHTYMA OY (FI) | 1996-03-12 | — | — | US | disclosed |
| EP-0618906-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | ANTII SAKARI HAAPALINNA (FI) | 1994-10-12 | — | — | EP | disclosed |
| WO-1993013074-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | Orion-Yhtymä Oy (FI) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025965-A1 | Antiserotonine agents | HTR2C, HTR3C, HTR3A | ADRA1A 93/4885P2RX7 2091/4885CHRNB2 110/4885 |
| US-20040224993-A1 | Diphenylurea compounds | HTR2C, HTR2A, HTR1A | ADRA1A 122/4885P2RX7 56/4885CHRNB2 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.